Dergiler / Turkish Journal of Gastroenterology / 2022 / Cilt: 33 - Sayı: 1

The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinom

Sayfa
1–7
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: For a high-risk population of HCC, early risk prediction is helpful to guide clinical work, and timely adjustments of the screening frequency and treatment plan are helpful to prolong the survival time of HCC patients

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and more than half of the newly diagnosed cases are chronic hepatitis B patients.
📊
Temel Bulgular & Veri:A variety of serological markers including M2BPGi, IL-6 and COMP can be used to predict the incidence of long-term HCC in patients.
💡
Sonuç & Katkı:Conclusion: For a high-risk population of HCC, early risk prediction is helpful to guide clinical work, and timely adjustments of the screening frequency and treatment plan are helpful to prolong the survival time of HCC patients
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and more than half of the newly diagnosed cases are chronic hepatitis B patients. Due to the lack of specific clinical manifestations, many patients are already at an advanced stage at the time of diagnosis and therefore have missed the best time for treatment. Organs in a pathological state usually secrete specific substances into the blood, which can indirectly indicate the pathological state of the organ, so some biological markers in the blood can be used as a tool to predict the incidence of HCC. Methods: The Research articles related to HCC were collected by searching PubMed databases with the keywords “hepatocellular carcinoma”, “serum biomarker”, “hepatitis B”, “prediction” and “prognosis”, and Additional articles were identified by manual search of references found in the primary articles, followed by a summary and review. Results: Viral hepatitis is the main cause of HCC worldwide, and this phenomenon is particularly prominent in Asian and African populations. A variety of serological markers including M2BPGi, IL-6 and COMP can be used to predict the incidence of long-term HCC in patients. The risk of HCC is dynamic rather than constant, and dynamic detection will help improve prediction accuracy. For hepatitis B patients, HBV DNA load and HBcr Ag are important predictive markers of HCC. Conclusion: For a high-risk population of HCC, early risk prediction is helpful to guide clinical work, and timely adjustments of the screening frequency and treatment plan are helpful to prolong the survival time of HCC patients

🔖

Bu Makaleye Atıf Yap

YANG, Q., SUN, C., SHENG, Y., CHEN, W., DENG, C. (2022). The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinom. Turkish Journal of Gastroenterology, Cilt: 33 - Sayı: 1, 1–7. https://ajindex.com/articles/411634

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016
  2. 2(1):16018. [CrossRef] 2. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017
  3. 11(4):317-370. [CrossRef] 3. European Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018
  4. 69(1):182-236. [CrossRef] 4. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018
  5. 154(6):1706-1718.e1. [CrossRef] 5. Mak LY, Wong DK, Seto WK, et al. Correlation of serum Mac2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatol Int. 2019
  6. 13(2):148-156. [CrossRef] 6. Mak LY, Ko M, To E, et al. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. J Gastroenterol Hepatol. 2019
  7. 34(10):1817-1823. [CrossRef] 7. Shinkai N, Nojima M, Iio E, et al. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. J Gastroenterol. 2018
  8. 53(7):883-889. [CrossRef] 8. Sato S, Genda T, Ichida T, et al. Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum Wisteria floribunda agglutinin-positive Mac-2-binding protein. Int J Mol Sci. 2016
  9. 17(12):2143. [CrossRef] 9. Hao C, Cui Y, Owen S, et al. Human osteopontin: potential clinical applications in cancer (Review). Int J Mol Med. 2017
  10. 39(6):1327- 1337. [CrossRef] 10. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012
  11. 55(2):483-490. [CrossRef] 11. Duarte-Salles T, Misra S, Stepien M, et al. Circulating osteopontin and prediction of hepatocellular carcinoma development in a large European population. Cancer Prev Res (Phila). 2016
  12. 9(9):758-765. [CrossRef] 12. Xiao Y, Kleeff J, Guo J, et al. Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver. J Gastroenterol Hepatol. 2004
  13. 19(3):296-302. [CrossRef] 13. Li Q, Wang C, Wang Y,